Opportunities include technological innovation, strategic partnerships, and regional market expansion to enhance operational resilience and modernize supply chains in the evolving blood plasma ...
The revolutionary treatment will mean patients no longer require a weekly injection ...
EMERYVILLE, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation ("XOMA Royalty") (Nasdaq: XOMA) announced today its Chief Financial Officer, Thomas Burns, will be stepping down from his ...
Mitsubishi Tanabe Pharma Corporation isn’t backing away from the complex field of gene therapies — it’s investing in new cutting-edge projects on critical limb ischaemia and haemophilia B, as well as ...
Detailed price information for Xoma Corp 8.625% (XOMAP-Q) from The Globe and Mail including charting and trades.
Extended half-life products for children with hemophilia B reduce both bleeding episodes and the need for infusions, ...
During a presentation at the J. P. Morgan Healthcare Conference 2026, Roche Pharma CEO Teresa Graham, projected confidence in the ability of Roche’s portfolio of marketed products to deliver growth ...
Researchers complete final analysis of a phase 3 study of men with hemophilia B receiving intravenous etranacogene dezaparvovec.
Researchers at Kumamoto University have developed a highly sensitive blood test that can detect subtle differences in how ...
The Central Drugs Standard Control Organisation (CDSCO) has granted multiple CT-18 approvals between January 2020 and ...
Researchers at Kumamoto University have developed a highly sensitive blood test that can detect subtle differences in how ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results